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X CHROMOSOME GAIN IN MALE BREAST CANCER 
 
Enrico Di Oto BS*, Valentina Monti BS PhD*, Maria C. Cucchi MD
§
, Riccardo 
Masetti MD
**
, Zsuzsanna Varga MD***, Maria P. Foschini MD*. 
 
EDO and VM equally contributed to the study. 
 
* Anatomic Pathology,  Department of Biomedical and Neuromotor Sciences, University 
of Bologna, Bologna (Italy). 
 § Breast Surgery Unit, Bellaria Hospital, Bologna, (Italy). 
** Breast Surgery Unit, Policlinico Universitario A. Gemelli, Rome, (Italy). 
*** Institute of Surgical Pathology University Hospital Zürich, (Switzerland). 
 
 
 
KeyWords: Male Breast Cancer, Invasive Ductal Carcinoma, X Chromosome, Genetic 
marker, FISH. 
 
Correspondence address: 
Maria P. Foschini, MD  
Anatomic Pathology  
Bellaria Hospital  
Via Altura, 3  
40139 Bologna (Italy),  
mariapia.foschini@unibo.it  
Tel. +390516225523  
Fax +390516225759 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Summary 
 
Male breast cancer (MBC) is an uncommon disease whose molecular profile is not well 
known. X chromosome gain has been described as a marker of aggressive behavior in 
female breast cancer. The aim of this study is to investigate the role of the X chromosome 
in male breast cancer. 
20 cases of male breast invasive ductal carcinoma were retrieved and compared with 10 
cases of gynecomastia. Cases were tested by fluorescence in situ hybridization (FISH) in 
order to assess a cytogenetic profile for the X chromosome. The X chromosome status 
was compared with histopathological features and stage at presentation. 
All MBC cases harbored an X chromosome gain (100%) in a variable percentage of 
neoplastic cells, ranging from 31% to 85% (mean 59%). On the contrary, all  cases of 
gynecomastia showed wild X chromosome asset. The patients’ age at surgery and tumor 
grading showed a statistical significant correlation (P= 0,0188 - P= 0,04), with the 
percentages of neoplastic cells showing an X chromosome gain. 
These data suggest that this X chromosome gain plays a role in the neoplastic 
transformation of male breast epithelial cells. 
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1. Introduction 
 
Male breast cancer (MBC) is an aggressive and uncommon disease accounting for 
approximately 1% of all breast cancers. The incidence of MBC, once thought to be 
relatively stable, now seems to be increasing 
[1-2-3-4]
. To date, MBC has not been 
characterized as well as female breast cancer due to its rarity.  A lack of specific 
biomolecular profiles leads clinicians to treat MBC patients in the same way as post-
menopausal women 
[1-2]
. 
Breast cancer is a genetically complex disease characterized by the accumulation of 
various structural and numerical chromosomal aberrations. In 1964 Jackson 
[5] 
described 
an increased risk of breast cancer in male patients with a 47XXY chromosomal asset 
(Klinefelter's Syndrome), indicating a potential role of X chromosome gain in the 
neoplastic transformation of the male breast epithelium.  
Presently, the role of X chromosome gain has been investigated in prostate carcinoma. 
Reported data indicate that an additional X chromosome is related to a poor response to 
anti-androgen therapy and a higher risk of recurrence of prostate carcinoma
 [6 8]
. 
Little is known about X chromosome gain in breast cancer.  
Nakopoulou et. al 2007 
[1] 
correlated chromosome X polysomy with a high histological 
grade, a high nuclear grade and impaired prognosis in cases of invasive ductal carcinoma 
affecting the female breast. These data suggest an implication of X chromosomes in cell 
survival and tumor aggressiveness.  
On the contrary, no data are presently available on X chromosome gain in MBC. 
The purpose of this study was therefore to investigate, using fluorescent in situ 
hybridization (FISH), the numerical aberrations affecting chromosome X in invasive 
MBC compared with normal skin as an in loco normal control and with gynecomastia. 
Results on X chromosome numerical aberrations were related to the patients’ age, tumor 
size, and lymph node status at the time of surgery. 
 
2. Materials and methods 
2.1 Patients selection 
Twenty consecutive cases of MBC and ten cases of gynecomastia were retrieved from the 
files of the “M. Malpighi” Anatomic Pathology Section of the Biomedical and 
Neuromotor Sciences Department of the University of Bologna in Bellaria Hospital. 
None of the gynecomastia cases presented MBC. 
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Cases were retained for the present study when paraffin blocks were available with 
adequate tissue to allow FISH.  
All investigations were conducted according to the principles expressed in the 
Declaration of Helsinki (Ethical Committee Code: 15004, Prot. N°. 412/CE)  
Hematoxilin Eosin -stained slides of all 30 cases were retrieved for histological 
evaluation, then classified and graded according to currently available criteria 
[7-8-9]
 by 
one pathologist (MPF).  
All the tissues were fixed in buffered formalin for 24 hours and then paraffin embedded 
(FFPE) according to routine procedures. FISH was performed on the most representative 
area of the slide.  
 
2.2 Fluorescent In situ Hybridization  
Dual-Color FISH was carried out according to standard FISH protocol, as previously 
described by Graziano et. al 2011 
[10]
, on 5 μm thick sections of whole tissue using a 
specific probe mix for the X chromosome (ON AR (Xq12) / SE X, Kreatech Diagnostics, 
Amsterdam, The Netherlands).  
 
2.3 Evaluation Criteria and Data Analysis 
FISH analysis was carried out using an Olympus BX61 epifluorescence microscope 
(Olympus, Melville, NY) equipped with a 100 planar objective. In each case, at least 100 
neoplastic non overlapped nuclei were counted, blindly from clinical information by two 
different biologists and one pathologist (VM, EDO, MPF). 
Normal epithelial tissue adjacent to the neoplastic tissue was used as an internal control 
to exclude Klinefelter’s Syndrome (47XXY). 
The following parameters were evaluated in order to correctly interpret the FISH results: 
total number of X chromosome centromeric probe signals (Spectrum Green), and average 
number of green signals.  
Scoring for X chromosome gain was carried out following criteria by Koivisto et. al 
(1997)
[11]
. One single signal for both the AR gene (spectrum Orange) and the SE X 
region (spectrum green) identified the normal chromosome asset. Nuclei with two or 
more SE X green signals were considered positive for  X  gain. 
Moreover, a lesion containing less than 20% of positive nuclei for X gain was considered 
to be negative, as described in Ropke et. al 2004 
[6]
. 
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2.4 Statistical Analysis  
Statistical analyses were performed using a commercially available software program 
called QuickCalcs, which is an on-line tool for linear regression by GraphPad. 
The relationship between FISH results and clinical and histopathological data was 
calculated using the generalized Fisher’s exact test that is part of the GraphPad 
QuickCalcs on-line tool. 
P values smaller than 0.05 were considered to reflect a significant difference between 
groups. 
 
3. Results 
The study included 30 cases, comprising 20 patients with MBC aged from 50 to 81 years 
(mean 69 years) and 10 patients with gynecomastia aged from 19 to 81 years (mean 58 
years). Histological diagnoses of patients with MBC consisted of grade II and grade III 
invasive ductal breast carcinoma (14/20 cases and 6/20 cases respectively). Metastases to 
axillary lymph-nodes were present in 4\20 MBC. 
All MBC (20/20) showed immunohistochemical positivity for oestrogen receptor (ER), 
18/20 for progesterone receptor. 
 
3.1 FISH results 
The presence of X chromosome gain in more than 20% of the neoplastic cells was 
detected in 100% (20\20) of the MBC cases studied here (Table 1). 
The percentage of neoplastic cells showing X chromosome gain ranged from 31% to 85% 
(mean 59%)(Fig. 1A-B). 
On the contrary, the percentage of cells showing X chromosome gain was below the cut-
off value in all the 10 gynecomastia cases (Fig. 1C-D), (Table 2).  
No X chromosome gain was observed in epidermal keratinocytes used as an internal 
control of both the BC and the gynecomastia cases.  
 
3.2 FISH profile and clinical-pathological correlation.  
A highly significant statistical correlation was found between T size and age in patients 
with MBC (P value 0.0064) (Fig.2). Age at presentation was related (P value 0.0188) 
(Fig.3) to the percentage of neoplastic nuclei harbouring X chromosome gain. 
Furthermore, chromosome X gain was statistically related to the histological grade (P 
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value 0.04 (Table 3). No statistically significant relationship was found with lymph-node 
and receptor status at the time of surgery. 
 
4 Discussion 
Klinefelter syndrome, characterized by a typical chromosome asset of 47XXY, is the 
most frequent sex chromosomal disorder in males, accounting for 1\2 per 1000 male 
neonates 
[12]
. It has been demonstrated that Klinefelter syndrome carriers have a higher 
risk of developing breast cancer
[4,13]
. Although the mechanisms underlying the higher 
susceptibility to breast cancer in Klinefelter syndrome are not well known, it seems 
possible that X chromosome gain may play a role in the neoplastic transformation of the 
male breast epithelial cells.  
The mechanism underlying the role of X chromosome in neoplastic transformation is 
difficult to understand. At present, only data on X chromosome gain regarding prostate 
cancer are available. The majority of prostate cancers are androgen receptor (AR) 
dependent. Both AR and its regulator MAGE-11 are mapped on chromosome X, 
respectively on Xq12 and Xq28, therefore a possible role in recurrence and resistance to 
anti-androgen therapy has been advocated 
[14]
.  
The impact of X chromosome gain in female breast cancer has been studied. Original 
data by Nakapoulu et al 
[1]
 showed that a gain of the X chromosome was related to an 
advanced stage at presentation, larger tumour size and high histological grade.  
More recently Lin et al 
[15] 
found aberrant patterns of X-chromosome inactivation in 
breast cancer cell lines and in breast cancer tissue specimens, significantly related to 
lower survival rates in female breast cancer patients. Moreover, Muñoz-Rodríguez et al. 
[16]
 studied the different miRNA expression in female breast cancer appearing 
immediately after partum or more than 5 years later. These authors found that more than 
60% of differentially expressed miRNAs were mapped on the X chromosome. 
All these data point toward a possible role of X chromosome involvement in the 
mechanism of neoplastic epithelial transformation. 
To the best of our knowledge, however, the presence of X chromosome gain has not yet 
been investigated in MBC. 
In the present series, all the cases of MBC that were tested showed X chromosome gain 
in more than 20% of the neoplastic cells.  
X chromosome gain was observed also in the gynecomastia cases, even though none of 
them presented X chromosome gain in more than 20% of the pathological epithelial cells.  
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Epidemiological data 
[17]
 show that gynecomastia can be considered a risk factor 
favouring the occurrence of MBC. The present data, even if limited to a small number of 
cases, seem to support this hypothesis, suggesting that it represents an early step in the 
neoplastic transformation of male breast epithelium. 
In MBC cases the percentage of neoplastic cells showing X chromosome gain increased 
in parallel with the age of the patient and the tumour size. The data here shown are 
consistent with those presented by Jacobs et al 
[18]
 who demonstrated that sex 
chromosome aneuploidy in non-dividing nuclei of peripheral blood cells occurs 
frequently in adult men and increases with age. The data presented by Jacobs et al.
18]
 did 
not completely clarify the relation between sex chromosome aneuploidy and occurrence 
of MBC, but suggested a possible role in favouring the neoplastic transformation. 
Even though this series is quite small and data should be validated on larger series, 
possibly completed with follow-up information, they nevertheless indicate that X 
chromosome gain is an important feature in the early steps of neoplastic transformation 
of male breast epithelium.  
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Figure legend: 
Figure legend: 
Fig.1. 
brief title: FISH results 
and a description:  (A) H&E-stained section showing invasive ductal carcinoma case and 
its positivity by FISH analysis (X 1000) for X chromosome gain (the number of green 
signals indicating the X chromosome are > 2 in the neoplastic nuclei) (B). (C) H&E-
stained section showing gynecomastia (X 250) case and its negativity for X chromosome 
gain by FISH (X 1000) (the number of green signals indicating the X chromosome are < 2 
in the pathological nuclei) (D). 
 
Fig.2.  
brief title: linear regression 
and a description: The figure evidences the correlation between tumor size and age in 
patients with male breast cancer (P value 0.0064). 
 
Fig.3.  
brief title: linear regression  
and a description: The figure evidences the correlation between age at presentation and 
percentage of neoplastic nuclei harboring X chromosome gain (P value 0.0188). 
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Figure 1 
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Figure 2 
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Figure 3 
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Table 1. Summary of  clinical-pathological  parameters and X chromosome status by FISH 
Id 
Age at 
Surgery 
X Aneusomy Asset by 
FISH*  
X 
Aneusomy** 
Histological Grade 
Tumor size 
(cm) 
1 80 25X, 68XX, 7XXX 68 2 4.5 
2 52 
52X, 41XX, 3XXX, 
4XXXX 
41 2 2.1 
3 51 69X, 30XX, 1XXX 30 2 1.2 
4 69 
19X, 73XX, 3XXX, 
4XXXX, 1VIX 
73 2 1.3 
5 79 
31X, 58XX, 10XXX, 1 
XXXX 
58 3 2.8 
6 81 44X, 53XX, 3 XXX 53 3 2.7 
7 56 52X, 48XX 48 2 1.8 
8 57 48X, 49XX, 3XXX 49 3 0.8 
9 66 64X, 36XX 36 2 2.1 
10 77 55X, 44XX, 1XXX 44 2 1.7 
11 73 28X, 66XX, 6XXX 66 2 2.8 
12 67 
51X, 46XX, 2XXX, 1 
XXXX 
46 2 2.5 
13 67 
15X, 75XX, 5XXX, 
5XXXX 
75 3 2.3 
14 50 
21X, 22XX, 
28XXX,23XXXX, 
5XXXXX, 1 XXXXXX 
22 2 0.8 
15 75 24X, 74XX, 2XXX 74 3 2.3 
16 77 50X, 46XX, 4XXX 46 2 2 
17 74 
53X, 44XX, 1XXX, 
1XXXX,   1 XXXXXX 
44 2 2 
18 80 29X, 69XX, 2XXX 69 3 1.3 
19 70 55X, 44XX, 2XXX 44 2 2.5 
20 74 
37X, 60XX, 2XXX, 1 
XXXX 
60 2 2.5 
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Legend: 
 
*Indicates the general asset of X chromosome observed in 100 nuclei for each MBC. 
* *The values indicate the number of nuclei (evaluated on 100 nuclei) with 2 X chromosome signals. 
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Table 2. X chromosome status by FISH in patients with gynecomastia 
Id Age at surgery X Aneusomy Asset by FISH* Nuclei WT** 
N. of  
X nuclei Aneusomy*** 
G1 63 100X 100 0 
G2 68 90X,10XX 90 10 
G3 75 95X,5XX 95 5 
G4 65 98X,2XX 98 2 
G5 23 95X,5XX 95 5 
G6 26 97X,3XX 97 3 
G7 81 89X,11XX 89 11 
G8 61 94X, 6XX 94 6 
G9 24 93X, 7XX 93 7 
G10 19 94X, 6XX 94 6 
Legend: 
*Indicates the general assets of X chromosome observed in 100 nuclei for each case of 
gynecomastia. 
* *The values indicate the number of nuclei with normal asset of  X chromosome in male 
(then one X chromosome for nuclei) 
***Number of nuclei (evaluated in 100 consecutive nuclei) with more than one X 
chromosome. 
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Table 3. Correlation between X Aneusomy status and Histological Grade 
  Grade 2 Grade 3 Total 
XX* >50% 4 5 9 
XX* <50% 10 1 11 
Total 14 6 20 
 
 
 
Legend: 
                       *XX indicate the X aneusomy in MBC. 
